The study, which began in mid-March, is the first to test the malaria drug as a preventative measure. Researchers enrolled 800 people in the U.S. and Canada, most of which were front-line healthcare workers, who had been exposed to someone with COVID-19.
Participants received either hydroxychloroquine or a vitamin placebo for five days and were then monitored for two weeks. The study was double-blinded, so neither the participants nor the researchers knew which medication was being received.
More articles on pharmacy:
Eli Lilly testing COVID-19 drug derived from survivor blood
Researchers testing several heart, anti-platelet drugs for COVID-19 patients
4 pharmacy leaders on mitigating drug shortages during a pandemic
